Evidence map›Paper›PMID 38201434›Full record

ArticleCancers2023

Intragenic

Lan Zheng, Rajyalakshmi Luthra, Hector A Alvarez, F Anthony San Lucas, Dzifa Y Duose, Ignacio I Wistuba, Gregory N Fuller, Leomar Y Ballester, Sinchita Roy-Chowdhuri, Keith J Sweeney and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Lan ZhengDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rajyalakshmi LuthraDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hector A AlvarezDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
F Anthony San LucasDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dzifa Y DuoseDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gregory N FullerDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-9447-2647
Leomar Y BallesterDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sinchita Roy-ChowdhuriDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-9447-7701
Keith J SweeneyDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Asif RashidDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Richard K YangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-0433-8626
Wei ChenDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Audrey LiuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yun WuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Constance AlbarracinDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Keyur P PatelDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mark J RoutbortDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aysegul A SahinDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Qingqing DingDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hui ChenDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor variant III (EGFRvIII, the deletion of exons 2-7) is a recurrent intragenic

Indexed as

breast sarcomatoid neoplasmEGFR::EGFR.E1E8 fusionEGFRvIIIglioblastomamalignant phyllodes tumor

Identifiers

PMID38201434
PMCPMC10778229
OpenAlexW4389981585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.